Contact dermatitis from budesonide in a nasal spray without cross-reactivity to amcinonide.
Gamboa
P M
PM
Sección de Alergología-Inmunología, Hospital Civil de Basurto, Bilbao, Spain.
Jáuregui
I
I
Antépara
I
I
D000287:Administration, Topical; D000328:Adult; D000336:Aerosols; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019819:Budesonide; D003429:Cross Reactions; D003877:Dermatitis, Contact / Q000209:etiology*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D011282:Pregnenediones / Q000008:administration & dosage / Q000009:adverse effects*; D014221:Triamcinolone / Q000009:adverse effects / Q000031:analogs & derivatives*
D000336:Aerosols; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; D014221:Triamcinolone; C012716:amcinonide; D019819:Budesonide